sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_8504> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_8504> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01112> ;
    a rdf:Statement ;
    rdfs:label "note cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram per milligram basis see clinical pharmacology cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below the safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and well controlled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen pharyngitis tonsillitis note acute bacterial otitis media impetigo to reduce the development of drug resistant bacteria and maintain the effectiveness of cefuroxime axetil for oral suspension and other antibacterial drugs cefuroxime axetil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB01112> bl:category bl:Drug .
}